Skip to main content

New Drug Approvals 2011 - Pt. XVII Fidaxomicin (Dificid TM)







ATC code (partial): A07A

On May 27th 2011, the FDA approved Fidaxomicin (Tradename: Dificid; Research Code: PAR-101, OPT-80, NDA 201699), a macrolide narrow spectrum antibacterial drug indicated for the treatment of Clostridium difficile-associated diarrhea (CDAD) in adults. Clostridium difficile (C. difficile) is an anaerobic, spore-forming Gram-positive bacteria, and overgrowth of this species can cause severe diarrhea and other more serious intestinal conditions, such as colitis.

Fidaxomicin is a fermentation product obtained from the Actinomycete Dactylosporangium aurantiacum. It exerts its therapeutic effect by inhibiting beta subunit of the bacterial enzyme DNA-directed RNA polymerase (RNAP) (UniProt:Q890N5), resulting in the death of C. difficile. Bacterial RNA polymerase is a large (~400 kDa) five subunit protein, and is the target of the already approved antibiotic rifampicin. Other treatments for CDAD already in the market include antibiotics such as Metronidazole (trade name Flagyl; ChEMBLID: CHEMBL137) and Vancomycin (ChEMBLID: CHEMBL262777). Patients generally respond to these antibiotic therapies, however there is a risk of recurrent infection associated with these treatments. Fidaxomicin has been shown to be more active in vitro than Vancomycin (minimum inhibitory concentration (MIC) of 0.12 µg/mL and 1.0 µg/mL, respectively) against C. difficile and also more selective, having limited activity in vitro and in vivo against components of the normal gut flora.

There are several known structures of bacterial RNA polymerases in complex with various antibiotics, typical is the structure of the Thermus aquaticus RNA polymerase in complex with sorangicin (PDBe:1ynn)



The recommended dose of Fidaxomicin is one 200 mg tablet twice daily for 10 days (equivalent to a daily dose of 380 umol). At therapeutic doses, Fidaxomicin has a minimal systemic absorption, with plasma concentrations of Fidaxomicin and OP-1118, its main and microbiologically active metabolite, in the ng/mL range. The mean terminal half-life (T1/2) of Fidaxomicin and OP-1118 is 11.7 and 11.2 hours, respectively. Fidaxomicin is primarily transformed by hydrolysis at the isobutyryl ester to form OP-1118. Metabolism of Fidaxomicin and formation of OP-1118 are not dependent on cytochrome P450 (CYP) enzymes. Fidaxomicin is mainly excreted in feces, with 92% of the dose recovered as either Fidaxomicin and OP-1118.

Fidaxomicin (IUPAC: [(2R,3S,4S,5S,6R)-6-[[(3E,5E,8S,9Z,11S,12R,13E,15E,18S)-12-[(2R,3S,4R,5S)-3,4-dihydroxy-6,6-dimethyl-5-(2-methylpropanoyloxy)oxan-2-yl]oxy-11-ethyl-8-hydroxy-18-[(1R)-1-hydroxyethyl]-9,13,15-trimethyl-2-oxo-1-oxacyclooctadeca-3,5,9,13,15-pentaen-3-yl]methoxy]-4-hydroxy-5-methoxy-2-methyloxan-3-yl]3,5-dichloro-2-ethyl-4,6-dihydroxybenzoate; SMILES: CC[C@H]1\C=C(/C)\[C@@H](O)C\C=C\C=C(/CO[C@H]2
O[C@@H](C)[C@H](OC(=O)c3c(O)c(Cl)c(O)c(Cl)c3CC)[C@@H](O)[C@H]2OC)\C(=O)O
[C@@H](C\C=C(/C)\C=C(/C)\[C@@H]1O[C@@H]4OC(C)(C)[C@@H](OC(=O)C(C)C)
[C@H](O)[C@@H]4O)[C@H](C)O; ChEMBL: CHEMBL485861; PubChem: 46174142) has a molecular weight of 1058 Da, an ALogP of 7.7, seven hydrogen bond donors and 18 acceptors, and thus is not rule of five compliant. A notable feature is the 18-member polyene macrolide ring.

The full prescribing information can be found here.

The license holder for Fidaxomicin is Optimer Pharmaceuticals, Inc. and the product website is www.dificid.com.

Comments

Popular posts from this blog

ChEMBL 34 is out!

We are delighted to announce the release of ChEMBL 34, which includes a full update to drug and clinical candidate drug data. This version of the database, prepared on 28/03/2024 contains:         2,431,025 compounds (of which 2,409,270 have mol files)         3,106,257 compound records (non-unique compounds)         20,772,701 activities         1,644,390 assays         15,598 targets         89,892 documents Data can be downloaded from the ChEMBL FTP site:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/ Please see ChEMBL_34 release notes for full details of all changes in this release:  https://ftp.ebi.ac.uk/pub/databases/chembl/ChEMBLdb/releases/chembl_34/chembl_34_release_notes.txt New Data Sources European Medicines Agency (src_id = 66): European Medicines Agency's data correspond to EMA drugs prior to 20 January 2023 (excluding ...

SureChEMBL gets a facelift

    Dear SureChEMBL users, Over the past year, we’ve introduced several updates to the SureChEMBL platform, focusing on improving functionality while maintaining a clean and intuitive design. Even small changes can have a big impact on your experience, and our goal remains the same: to provide high-quality patent annotation with a simple, effective way to find the data you need. What’s Changed? After careful consideration, we’ve redesigned the landing page to make your navigation smoother and more intuitive. From top to bottom: - Announcements Section: Stay up to date with the latest news and updates directly from this blog. Never miss any update! - Enhanced Search Bar: The main search bar is still your go-to for text searches, still with three pre-filter radio buttons to quickly narrow your results without hassle. - Improved Query Assistant: Our query assistant has been redesigned and upgraded to help you craft more precise queries. It now includes five operator options: E...

Here's a nice Christmas gift - ChEMBL 35 is out!

Use your well-deserved Christmas holidays to spend time with your loved ones and explore the new release of ChEMBL 35!            This fresh release comes with a wealth of new data sets and some new data sources as well. Examples include a total of 14 datasets deposited by by the ASAP ( AI-driven Structure-enabled Antiviral Platform) project, a new NTD data se t by Aberystwyth University on anti-schistosome activity, nine new chemical probe data sets, and seven new data sets for the Chemogenomic library of the EUbOPEN project. We also inlcuded a few new fields that do impr ove the provenance and FAIRness of the data we host in ChEMBL:  1) A CONTACT field has been added to the DOCs table which should contain a contact profile of someone willing to be contacted about details of the dataset (ideally an ORCID ID; up to 3 contacts can be provided). 2) In an effort to provide more detailed information about the source of a deposited dat...

Improvements in SureChEMBL's chemistry search and adoption of RDKit

    Dear SureChEMBL users, If you frequently rely on our "chemistry search" feature, today brings great news! We’ve recently implemented a major update that makes your search experience faster than ever. What's New? Last week, we upgraded our structure search engine by aligning it with the core code base used in ChEMBL . This update allows SureChEMBL to leverage our FPSim2 Python package , returning results in approximately one second. The similarity search relies on 256-bit RDKit -calculated ECFP4 fingerprints, and a single instance requires approximately 1 GB of RAM to run. SureChEMBL’s FPSim2 file is not currently available for download, but we are considering generating it periodicaly and have created it once for you to try in Google Colab ! For substructure searches, we now also use an RDKit -based solution via SubstructLibrary , which returns results several times faster than our previous implementation. Additionally, structure search results are now sorted by...

A python client for accessing ChEMBL web services

Motivation The CheMBL Web Services provide simple reliable programmatic access to the data stored in ChEMBL database. RESTful API approaches are quite easy to master in most languages but still require writing a few lines of code. Additionally, it can be a challenging task to write a nontrivial application using REST without any examples. These factors were the motivation for us to write a small client library for accessing web services from Python. Why Python? We choose this language because Python has become extremely popular (and still growing in use) in scientific applications; there are several Open Source chemical toolkits available in this language, and so the wealth of ChEMBL resources and functionality of those toolkits can be easily combined. Moreover, Python is a very web-friendly language and we wanted to show how easy complex resource acquisition can be expressed in Python. Reinventing the wheel? There are already some libraries providing access to ChEM...